Grail has added $390m in series D funding to its coffers thanks to a consortium featuring Illumina, significantly shooting past its $250m target size.
US-based cancer diagnostics technology developer Grail received $390m in a series D round yesterday backed by genomics company Illumina.
Public Sector Pension Investment Board and Canada Pension Plan Investment Board also took part in the round, as did several unnamed new and existing backers.
Grail had secured an initial $125m in December 2019, when a regulatory filing showed a $250m target size for the round.
Spun out of Illumina in 2016, Grail has created an early detection blood test…
